Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SF0021
- Development stage
- Preclinical
- Lead developer
- Sarfez Pharmaceuticals
- Modality
- Small Molecules
01
Overview
SF0021 is a small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor being developed by Sarfez Pharmaceuticals. It is currently in the preclinical stage of development for the treatment of diabetic kidney disease (DKD). The drug's mechanism involves the inhibition of SGLT2 in the proximal tubule of the kidney, which reduces the reabsorption of filtered glucose and sodium. This action promotes glucosuria and natriuresis, leading to improved glycemic control and a reduction in intraglomerular pressure, which is intended to provide renoprotective effects and slow the progression of kidney damage in diabetic patients.
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on SF0021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SF0021.